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A B S T R A C T
Circulating tumor cells serve as useful biomarkers with which to identify disease status associated with
survival, metastasis and drug sensitivity. Here, we established a novel application for detecting PSA/
PSMA-positive prostate cancer cells circulating in peripheral blood employing an adenovirus called Ad5/
35E1aPSESE4. Ad5/35E1aPSESE4 utilized PSES, a chimeric enhancer derived from PSA/PSMA promoters
that is highly active with and without androgen. A ﬂuorescence signal mediated by GFP expression upon
Ad5/35E1aPSESE4 infection was selectively ampliﬁed in PSA/PSMA-positive prostate cancer cells in vitro
and ex vivo. Furthermore, for the in vivo model, blood drawn from TRAMP was tested for CTCs with Ad5/
35E1aPSESE4 infection and was positive for CTCs at week 16. Validation was performed on patient blood
at various clinical stages and found out 1–100 CTCs expressing GFP upon Ad5/35E1aPSESE4 infection.
Interestingly, CTC from one patient was conﬁrmed to be sensitive to docetaxel chemotherapeutic reagent
and to abundantly express metastasis-related genes like MMP9, Coﬁlin1, and FCER1G through RNA-seq.
Our study established that the usage of Ad5/35E1aPSESE4 is effective in marking PSA/PSMA-positive pros-
tate cancer cells in patient blood to improve the eﬃcacy of utilizing CTCs as a biomarker.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Prostate cancer is the second most common cancer among
men worldwide, with the highest incidence in Western countries
such as Australia, New Zealand, North America and Western
Europe [1]. Its metastasis to bone, lymph node, liver and lung
tissue is a major cause of cancer-related death. Patients have
relatively high 5-year survival rates, partially due to the early
detection of prostate cancer, but many prostate cancer patients
still die of this condition. Prostate-speciﬁc antigen (PSA), which is
a protein produced exclusively by the prostate gland, is widely
used as a serum marker because its level in blood becomes
elevated upon prostate cancer development and progression. PSA
has several limitations to its accuracy for the diagnosis of prostate
cancer because the PSA level can be elevated regardless of the
occurrence of prostate cancer and its progression. With the in-
crease in life span, there are often higher levels of PSA due to the
development of benign prostatic hyperplasia (BPH). Furthermore,
PSA levels vary by race and Asians have a relatively lower PSA
level than Caucasians [2]. Often, men have a high level of PSA
with no sign of cancer or a man with prostate cancer may have
blood PSA levels within the normal range. Among cases with
elevated PSA levels, only 25% are found to have prostate cancer as
veriﬁed by prostate biopsy [3], suggesting that we need alterna-
tive strategies to complement PSA levels to assess disease progression
status, such as the monitoring of circulating tumor cells (CTCs).
A CTC is deﬁned as a cell that escapes from the primary tumor
site and circulates in the bloodstream. For metastasis to distant sites,
tumor cells can travel through the circulation of the body; hence,
CTCs are indicative of the potential growth of tumors in distant organ
sites, so-called ‘metastasis’ [4]. In 1869, it was found that cancer
cells observed in the blood may shed light upon the mode of origin
of multiple tumors existing in the same person. Since then, a number
of reports have demonstrated that CTCs can be used as a prognos-
tic marker and can be indicative of metastatic relapse or progression
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in tumors [5]. In addition to their biological relevance, CTCs in the
blood are advantageous because they provide a so-called “liquid
biopsy.” The harvesting of blood samples in the clinic is a simple
procedure. There are a number of clinical trials registered at
www.clinicaltrials.gov using CTCs as a biomarker, but there are a
few hurdles to be resolved before this approach becomes a routine
procedure in the clinic. First, CTCs are present at such low numbers
in the peripheral blood, ranging from 1 from 10 cells per 10mL blood
in cancer patients [6], making their detection diﬃcult. Second, most
methods developed thus far lack speciﬁcity for the detection of CTCs.
Some researchers utilize a speciﬁc antibody to detect cancer-
associated antigens expressed on CTCs, but patient antigen levels
vary. Not all of the CTCs in a single patient express a target antigen
[7]. In the case of prostate cancer, the presence of CTCs was related
to poor prognosis. Patients with high numbers of CTCs presented
poor outcomes of survival as analyzed by the CellSearchTM system
(Raritan, NJ, USA) [8]. The CellSearchTM system utilizes the strate-
gy of catching EpCAM expressed on a CTC membrane. EpCAM is a
common target because the epithelial mesenchymal transition (EMT)
plays an important role in the process of vascular invasion of tumor
cells and results in hematogenous dissemination. However, many
CTCs have a low expression of EpCAM, and tumor cells with low
EpCAM expression are less likely to be detected by CellSearchTM.
Much effort has been made in the development of alternative strat-
egies for CTC detection, such as through the size difference between
leukocytes and CTCs, but these strategies remain unsatisfactory due
to the lack of a universal marker.
As a non-enveloped virus, an adenovirus has a double-
stranded DNA genome and utilizes the Coxsackievirus and adenovirus
receptor (CAR) on the surface of host cells [9]. Upon entry into the
host cell, the adenovirus replicates in the nuclei of host cells
utilizing a host replication system. Once the virus successfully
replicates, its viroid particles are released through cell lysis. With
the clinical purpose of developing adenovirus-mediated gene
therapy for cancer, adenovirus replication has been restricted to a
prostate tumor by controlling the lytic process of the viral life
cycle and thus causing cell death in a directed fashion. For the
conditional replication of an adenovirus in a tumor, a key regula-
tor for viral replication, E1a/b, is placed in a tumor or tissue-
speciﬁc promoter [10,11]. Interestingly, a replication-competent
adenovirus (RCA) under the hTERT promoter was also harnessed
for the detection of CTCs with high effectiveness, demonstrating
this as an effective alternative strategy to overcome deﬁciencies in
marker-based CTC detection [12]. With respect to prostate cancer,
the rat probasin promoter, which becomes active in the presence
of androgen, was employed to construct an RCA for CTCs. A
probasin-controlled RCA was designed to express and secrete
luciferase protein out of the cell during its replication [13]. Never-
theless, there is still a need to detect CTCs in prostate cancer
patients with a very low level of androgen as a result of hormone
therapy. In a previous report, we introduced a prostate-speciﬁc
RCA, Ad5E1aPSESE4, and the replication of Ad5E1aPSESE4 was
controlled by PSA/PSMA transcription regulatory elements (PSES)
[14,15]. Here, we describe a novel approach to detecting circulat-
ing prostate tumor cells to enhance the eﬃcacy of the prediction
of disease stage and progression in prostate cancer using Ad5/
35E1aPSESE4 modiﬁed from Ad5E1aPSESE4.
Materials and methods
Cell culture and mouse line
LNCaP, C4-2, PC3, DU145, TRAMPc2 and KU19-19 were maintained in RPMI1640
media and 10% (v/v) fetal bovine serum (FBS) plus 1% (v/v) antibiotics. HT29 was
maintained in Dulbecco’s High Glucose DMEM and 10% (v/v) FBS plus 1% (v/v) an-
tibiotics. TRAMP mice were purchased from Jackson ImmunoResearch (West Grove,
PA, USA).
Adenovirus construction
Adenovirus Ad5/35E1aPSESE4was constructed on the basis of the previous report
ligating three vectors: 1) pAd1020CMVGFPSﬁdA, containing an adenovirus left in-
verted terminal repeat and packaging signal [14]; 2) E1bF5/35E4(Δorf1-4) for serotype
5 genome-based backbone vector [15], which contains the ﬁber knob replaced with
that of serotype 35; and 3) p304Sﬁ, containing the right-sided inverted terminal repeat
of the adenoviral genome [15]. All vectors were digested with SﬁI restriction enzyme
and were ligated to make pAd5/35E1aPSESE4. The adenoviral vector pAd5/
35E1aPSESE4 was digested with PacI and was transfected into 911E4 cells for virus
production. For high-titer adenovirus puriﬁcation, Ad5/35E1aPSESE4 was puriﬁed
using an ultracentrifugation method with CsCl2, followed by dialysis using a mem-
brane exchange method.
Infection of Ad5/35E1aPSESE4 in cancer cells or cells from TRAMP
An indicated number of each cell type was plated in a 12-well plate for 1 day.
Cells seeded in a 12-well plate were infected with 1 MOI of Ad5/35E1aPSESE4 and
were observed under a ﬂuorescence microscope for 24 h, 48 h and 72 h. For experi-
ments involving BALB/c, 1 × 106 of C4-2 cells that were prepared in PBS were injected
through the mouse tail vein of a BALB/c nude mouse. Six hours post-injection of the
cells; 200 μL of blood was withdrawn from each mouse and analyzed for circulat-
ing C4-2 cells. For TRAMP experiments, a [18F]PET-CT scan was employed to trace
tumor growth in prostate TRAMP in a non-invasive manner. Every 2 weeks, 200 μL
of blood was withdrawn and was exposed to 1 MOI of adenovirus Ad5/35E1aPSESE4
for detecting CTCs. For the PET monitoring of prostate tumors in a TRAMP mouse,
[18F]FDG was produced by a standard method using our on-site cyclotron (RDS-
111, Siemens, Germany) and automatic radiosynthesis modules (CPCU, Siemens,
Germany). Mice were supplied only with water and without caloric food materials
for 6 h. Before the mice were anesthetized with 2% isoﬂurane in 100% oxygen for
the FDG-scan, their blood glucose levels were veriﬁed as being below 100 g/mL before
every [18F]FDG injection. We administered 14.8 MBq of [18F]FDG through IV. The
[18F]FDG PET-CT scanwas performed in a three-dimensional acquisitionmode (eXplore
VistaCT, GE Healthcare Life Science, Piscataway, USA). PET scans were acquired for
10 min per bed position for all studies and were processed through normalization
but without scatter correction and attenuation correction. All images were recon-
structed with iterative reconstruction (OSEM 2-D, 32 subsets, two interactions). For
CT scans, X-ray sources were used with 300 μA and 40 kV for 6 min. The CT reso-
lution was 200 μm, and the number of acquired projections was 360.
Quantitative PCR analysis
A total of 1 × 103 of C4-2 cells was plated into a 6-well plate. One day after seeding,
the cells were infected with 1 MOI of Ad5/35E1aPSESE4. The cells were harvested
at indicated time points, after which the total DNA was extracted using the Qiagen
Blood Kit (QIAGEN Sciences, Gaithersburg, MD, USA). For counting Ad5/35E1aPSESE4
particles, quantitative PCR was performed using a QGreen Master Mix kit (CellSafe,
Suwon, Korea) and predesigned primer/probe pairs for adenovirus (5′-CCT GT GGT
AGT CCT TGT ATT TAG TAT C-3′ and 5′-GCC ATT ACC TTT GAC TCT TCT GT-3′) and
GAPDH (5′-ATG GCA TGG GGG TCT GAA AG-3′ and 5′-CAT CCT TGG GGC GTG TAA
GT-3′). Relative expression levels were normalized to GAPDH using the LightCycler
software (Roche, Indianapolis, IN, USA).
Counting CTCs in prostate cancer blood using Ad5/35E1aPSESE4
For the separation of PBMCs (peripheral blood mononuclear cells) from whole
blood, 5 mL of whole blood in a K2 EDTA tube was added to a 50 mL conical tube
containing 4 mL of Ficoll-Paque PLUS (GE Healthcare Life Science) and was gently
mixed with PBS to reach a total volume of 10 mL. The mixture in a 50 mL conical
tube was centrifuged at 400 × g for 10min at room temperature (RT). The PBMC layer
was harvested, placed into a new 50 mL conical tube and washed with PBS. After
the PBMC sample was pelleted at 200 × g for 20 min at RT, the sample was exten-
sively washed with PBS and re-suspended in a microcentrifuge tube containing 1mL
PBS. The PBMC sample in the microcentrifuge tube was centrifuged at 6000 × g for
1 min and was re-suspended with 1mL of DMEM supplemented (GE Healthcare Life
Science) with 10% (v/v) FBS and 1% (v/v) antibiotics. Finally, the PBMC sample was
plated in a 12-well plate for 1 day. PBMCs and CTCs were infected with 0.01 MOI
of Ad5/35E1aPSESE4 and were observed under a ﬂuorescence microscope for 24 h,
48 h and 72 h. Blood was determined to contain CTCs when large GFP-expressing
cell(s) were found. Tumor cells were maintained in Dulbecco’s High Glucose MEM
medium supplemented with 10% (v/v) FBS and 1% (v/v) antibiotics.
mRNAseq experiments and data analysis
For control and test RNAs, the construction of library was performed using SENSE
mRNA-Seq Library Prep Kit (Lexogen, Inc., Austria) according to the manufacturer’s
instructions. Brieﬂy, 2 μg of each total RNA was prepared and incubated with mag-
netic beads decorated with oligo-dT, and then other RNAs except mRNAwas removed
by washing solution. Library production was initiated by the random hybridiza-
tion of starter/stopper heterodimers to the polyA RNA still bound to the magnetic
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beads. These starter/stopper heterodimers contained Illumina-compatible linker se-
quences. A single-tube reverse transcription and ligation reaction extended the starter
to the next hybridized heterodimer, where the newly-synthesized cDNA insert was
ligated to the stopper. Second strand synthesis was performed to release the library
from the beads, and the library was then ampliﬁed. Bar codes were introduced when
the library was ampliﬁed. High-throughput sequencing was performed as paired-
end 100 sequencing using HiSeq 2000 (Illumina, Inc., Sang Diego, CA, USA). For data
analysis, RNA-Seq reads were mapped using TopHat software tool in order to obtain
the alignment ﬁle. The alignment ﬁle was used for assembling transcripts, estimat-
ing their abundances and detecting differential expression of genes or isoforms using
cuﬄinks.
Results
Establishment of an in vitro assay to detect circulating prostate
cancer cells using Ad5/35E1aPSESE4
The transcription regulatory element controlling rat probasin
protein expression has been used to construct a replication-
competent adenovirus and to detect CTCs. However, it is doubtful
whether this method could be applied to most prostate cancer
patients regardless of androgen/androgen receptor status. In the
previous study, we introduced a chimeric transcription enhancer
PSES that was composed of PSA and PSMA transcription regulato-
ry elements. When PSES was used to control the E1a and E4
genes, prostate-restricted RCA Ad5E1aPSESE4 was active selec-
tively in PSA/PSMA-positive prostate cancer cells and active in the
absence of androgen [14]. For better infectivity of cancer cells, we
replaced a serotype 5 ﬁber knob with a serotype 35 ﬁber knob,
resulting in a chimeric adenovirus Ad5/35E1aPSESE4 (Fig. 1A).
Here, we explored whether Ad5/35E1aPSESE4 could infect pros-
tate CTCs and label CTCs with ﬂuorescence in blood drawn from a
prostate cancer patient. First, a prostate cancer cell’s C4-2 was
mixed with PBMCs prepared as illustrated in Fig. 1B, after which
it was tested for adenoviral infection and expression of green
ﬂuorescence protein (GFP). As shown in Fig. 1B, 0.1 MOI of Ad5/
35E1aPSESE4 mediated GFP expression in C4-2 cells at 48 h,
suggesting that Ad5/35E1aPSESE4 detected PSA/PSMA-positive
prostate cancer cells in the presence of as many as 3 × 106 PBMCs.
To evaluate other prostate cancer cells, hormone-sensitive LNCaP
and hormone-refractory prostate cancer cells, DU145 and PC3,
were tested following the same protocol in Fig. 1C. One thousand
cells were exposed to 1 MOI of Ad5/35E1aPSESE4 for 48 h and
placed under ﬂuorescence microscopy. All PSA/PSMA-positive
cells tested enabled GFP expression at 48 h, but PSA/PSMA-
negative PC3 and DU145 exhibited no GFP expression, as reported
previously [14]. HT29 and Ku19-19 were included as non-prostate
cancer cells. We used such a small number of virus particles
that the GFP gene controlled by the universal CMV promoter
in the Ad5/35E1aPSESE4 genome was not suﬃciently
expressed, with only transient viral transduction without viral
replication.
Quantifying CTCs in human blood employing Ad5/35E1aPSESE4
Next, Ad5/35E1aPSESE4 was evaluated for its ability to deter-
mine howmany CTCs existed in the presence of PBMCs. Quantitative
analysis may be an important factor for exploiting adenovirus in de-
tecting CTCs, as the number of CTCs in a certain amount of blood
may provide correlative information regarding prognosis or treat-
ment outcome in the clinic. To answer this question, the known
number of C4-2 cells was mixed with PBMCs puriﬁed from a normal
male blood donor and infected with 1 MOI of Ad5/35E1aPSESE4.
The cells were observed and counted under ﬂuorescence micros-
copy at 48 h and 72 h (Fig. 2A).When GFP-positive cells were counted
at 48 h and 72 h post-infection, GFP-positive cell numbers were
closely correlated with the C4-2 cells added to the culture dish. At
72 h, GFP-positive numbers decreased compared with input cells,
most likely due to RCA-driven cell lysis. To conﬁrm the virus rep-
lication in this experimental setting, two differing amounts of C4-2
cells weremixed and then infected with 1MOI of Ad5/35E1aPSESE4.
Total DNAwas extracted and then used for counting the total number
of virus particles by employing quantitative PCR (Fig. 2B). As shown
in Fig. 2B, the number of virus particles at 48 h was much higher
than that at 72 h, suggesting continuous virus replication up to 72 h,
and themore effective time point was at 48 h for counting CTCs with
ﬂuorescence.
Detection of CTCs by Ad5/35E1aPSESE4 in an animal model
We investigated whether Ad5/35E1aPSESE4 had the ability to
mark prostate cancer cells circulating in animal blood. C4-2 at a count
of 1 × 106 cells was injected through the tail vein. Blood was drawn
6 h post-adenovirus injection and was treated with RBC-selective-
lysis solution. Subsequently, PBMC samples were infected with 1
Fig. 1. In vitro prostate cancer cells expressing GFP upon infection with Ad5/
35E1aPSESE4. A. Replication-competent adenovirus (RCA) Ad5/35E1aPSESE4 is
controlled by PSES. B. PBMCs from a Ficoll isolation of 5 mL blood were washed with
phosphate-buffered saline (PBS) and was resuspended with 1 mL of DMEM media
with 10% FBS and 1% antibiotics. Prostate cancer cells with 1 × 103 PSA/PSMA-
positive C4-2s were mixed with 1 × 106 human PBMCs and infected with a different
number of Ad5/35E1aPSESE4 for 48 h. GFP was observed under ﬂuorescence mi-
croscopy. C. There were 1 × 103 different cancer cells infected with 1 MOI of Ad5/
35E1aPSESE4, and GFP-expressing cells were counted under ﬂuorescencemicroscopy.
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MOI of Ad5/35E1aPSESE4 for 48 h. As shown in Fig. 3, different
numbers of C4-2 cells in blood showed ﬂuorescence upon infec-
tionwith Ad5/35E1aPSESE4. Controlmice, whichwere never exposed
to Ad5/35E1aPSESE4, had no ﬂuorescent cells. This experiment con-
ﬁrmed that prostate cancer cells in the blood maintained their
viability throughout the RBC lysis procedure and mediated GFP ex-
pression upon adenovirus infection. Next, we explored whether CTCs
could be observed in TRAMPmice that developed a prostate tumor
when SV40-T antigens became highly abundant. Before the animal
experiments, TRAMPc2 cells derived from a TRAMPmouse were in-
fectedwith Ad5E1PSESE4, conﬁrming that Ad5/35E1aPSESE4 enabled
the expression of GFP in a TRAMPmouse-derived cell line (Fig. 4A).
Tumor formation near the prostate in TRAMP mice was moni-
tored using a [18F]FDG-PET scan at a 2 week interval. Interestingly,
tumors in the prostate were not clear, as seen by [18F]FDG-PET during
the entire period of the experiments (Fig. 4B), but CTCs started to
be observed under ﬂuorescence microscopy at week 16 (Fig. 4B),
suggesting that adenovirus-mediated CTC detection is very
informative for tumors near the prostate and their metastasis. As
more weeks passed, more CTCs were counted. Our ﬁndings are not
conclusive but suggest that Ad5/35E1aPSESE4-mediated CTC de-
tection may be a useful diagnostic tool in the clinic for identifying
CTCs in prostate cancer patients. To verify prostate tumors in TRAMP
mice, a TRAMP mouse was sacriﬁced and specimens of the pros-
tate were placed on a slide with H&E staining. Prostate tumors in
the prostate and the seminal vesicle were histologically con-
ﬁrmed (Fig. 4C).
Validation of CTC detection in the blood of prostate cancer patients
PSA is a prostate-speciﬁc antigen, and its increase in blood is used
to establish an abnormal status of the prostate such as hyperpla-
sia and neoplasia. This biomarker is also a good indicator of cancer
recurrence and disease progression. However, the PSA level has de-
ﬁnitive limitations and requires additional information for the
determination of cancer progression status. We explored whether
CTCs in blood could be used for the determination of clinical status.
Before Ad5/35Ea1PSESE4 was applied to CTCs in the blood of pros-
tate cancer patients, 20 non-cancerous people aged 20-40 years were
enrolled in this study and their blood was tested. Ad5/35E1aPSESE4
mixed with PBMCs from the normal control group did not produce
any detectable ﬂuorescence, indicative of the very small possibil-
ity of false positivity. Then, we hypothesized that prostate cancer
patients at themetastatic stagewould have CTCs in their blood. Blood
from patients at the metastatic stage was drawn, and leukocyte mix-
tures were infected with 0.01 MOI of Ad5/35E1aPSESE4. Patients
determined to be at late stages based on pathological readings had
a large number of CTCs (Supplementary Fig. S1). As summarized in
Table 1, most of the patients harbored CTCs in which the ﬂuores-
cence signal was ampliﬁed and that were cultivatable. Such results
implied that detectable ﬂuorescence and cultivated CTCs in patient
blood were strong biomarkers for cancer metastasis. Next, we in-
vestigated whether Ad5/35E1aPSESE4 could detect CTCs from
patients bearing organ-conﬁned prostate tumors. Blood obtained
from patients after prostatectomy was infected with Ad5/
35E1aPSESE4 and was observed under ﬂuorescence microcopy. The
majority of those patients (54 of 88 patients) did not exhibit ﬂuo-
rescence and had no cultivated cells upon Ad5/35E1aPSESE4
infection. Many patients (25 of 88 patients) had ﬂuorescent cells
but did not have cultivatable cells (Table 2). However, four pa-
tients had ﬂuorescent and cultivatable CTCs marked by Ad5/
35E1aPSESE4; interestingly, 3 patients had as low as 0.1 ng/mL PSA
in the blood (Table 3). CTCs from one of 3 patients were further char-
acterized in Fig. 5. Cultivated cells were exposed to various
concentrations of docetaxel and 2 μM of docetaxel inhibited cell sur-
vival by 30% in cultivated CTCs (Fig. 5B). Furthermore, those cultivated
CTCs were analyzed by RNA-seq and were shown to overexpress
several metastasis-related genes (Fig. 5C). PSCA was included as a
reference gene known to be expressed in prostate cancer cell. This
ﬁnding suggests that cultured and ﬂuorescent CTCs can be
Fig. 2. Quantitation of C4-2 cells in the presence of PBMCs by adenovirus Ad5/
35E1aPSESE4. A. Different numbers of C4-2 cells from 0 to 100 were mixed with
1 × 106 PBMCs and counted at 48 and 72 h. B. C4-2 cells of 10 or 100 were infected
with 1 MOI of Ad5/35E1aPSESE4. Forty-eight hours post-infection, cells were har-
vested and the total DNAwas extracted. For counting virus particles inside cells, qPCR
was performed using primers corresponding to adenovirus ITR as described in the
Materials and Methods.
Mouse 1 (68 cells) Mouse 2 (111 cells)
Mouse 3 (348 cells) Mouse 4 (52 cells)
1 x 106 C4-2 cells
6 h 200µl of blood
Lysis of RBC
Separated PBMC 
1 MOI of Ad5/35E1aPSESE4
Fig. 3. Prostate CTCs in mice marked by Ad5/35E1aPSESE4. A total of 1 × 106 C4-2
cells were injected into the tail veins of BALB/c nude mice. After 6 h of injection,
200 μL of blood was withdrawn and lysed with RBC lysis buffer. PBMCs were seeded
onto 12 well-plates and infected with 1 MOI of Ad5/35E1aPSESE4. Cells expressing
GFP upon infection were observed and counted under a ﬂuorescence microscope.
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Fig. 4. CTC detection in a TRAMP mouse by Ad5/35E1aPSESE4. A. A total of 1 × 103 TRAMPc2 cells were seeded into 12 well-plates and infected with 1 MOI of Ad5/
35E1aPSESE4. Cells were monitored under ﬂuorescence microscope at 48 h post-infection. B. On a regular basis from 8 weeks after birth, 200 μL of blood was withdrawn
from TRAMP mice developing orthotopic tumors inside the prostate and deprived of RBC. The remaining PBMCs were infected with Ad5E1PSESE4, and GFP was monitored
and counted under ﬂuorescence microscopy. Simultaneously, [18F]FDG-PET/CT was employed to monitor tumor growth in the prostate. C. After the study was completed,
the TRAMP mouse was sacriﬁced and tumors around the prostate were conﬁrmed by H&E (hematoxylin and eosin) staining. SV, seminal vesicle; P, prostate; B, bladder.
Table 1
CTC detection in prostate cancer patients with tumor metastasis.
Tumor stage Number of
detected CTCs
Number of
patients
CTC culture
or not
Prostate cancer with
metastasis
0 11 No
1–5 12 Yes
5–10 5 Yes
>10 5 Yes
Castration-resistant
prostate cancer
0 6 No
1–5 5 Yes
>10 9 Yes
Table 2
CTC detection in prostate cancer patients with no metastasis.
Tumor stage CTC culture
or not
Number of
detected CTCs
Number of
patients
Low risk prostate cancera No 0 3
Localized prostate cancerb No 0 51
1–5 23
5–10 1
>10 1
Yes 0 5
<0.1 3
5–10 0
>10 1
a Patient received active surveillance of low risk prostate cancer.
b Patients underwent radical prostatectomy included localized or locally ad-
vanced prostate cancer.
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detected from patient blood with serum PSA (<0.1 ng/mL), indi-
cating the potential of Ad5/35E1aPSESE4 to provide additional
information that the PSA value alone cannot provide regarding
disease status. Another interesting group of 5 patients with PSA > 0.1
had no ﬂuorescent cells but did have cultured cells. These cells may
be non-prostate cancer cells or prostate CTCs that did not express
PSA/PSMA, requiring further analysis.
Discussion
Radical prostatectomy is the standard treatment for localized
prostate cancer. Although patients with prostate cancer undergo
surgery, many patients still show PSA increasing within 10 years
after surgery, which is called the biochemical recurrence of pros-
tate cancer and is observed in more than half of patients [16]. To
predict the risk of disease recurrence after treatment, physicians
use clinical prognostic factors including baseline PSA level, stage
(clinical/pathological), and Gleason scoring, which have been re-
garded as key predictive variables. However, the accuracy of those
clinical variables is limited in predicting the prognosis of prostate
cancer due to diverse PSA levels arising from heterogeneous
tumor biology and the inconsistency of tumor grading based on
the Gleason grading system. Many studies have aimed at develop-
ing candidate biomarkers in peripheral blood for prostate cancer
with clinical use for the prognostication of disease recurrence and
progression after treatment. In our previous studies, we found
that some candidate tumor markers in peripheral blood have a
potential role in predicting disease recurrence after surgery, such
as PSCA and PSMA mRNA expression in cells in peripheral blood
by the RT-PCR method [17,18]. Numerous reports have called into
question the usefulness of RT-PCR in prostate cancer due to its
limitations with respect to sensitivity and quantitation. When the
results of CTC detection were analyzed in the present study, cases
of advanced prostate cancer showed a higher rate of CTC detec-
tion in the peripheral blood of patients than those of early-
localized prostate cancer. The CTCs were more frequently cultured
in advanced disease, such as in cases with metastasis or castration-
resistant diseases (Tables 1–3). Compared with CTC detection by
RT-PCR ampliﬁcation of PSA and PSMA genes using total RNA
templates obtained from prostate cancer patients with metastasis
(Supplementary Table S1) or CRPC patients (Supplementary Table S2),
Ad5/35E1aPSESE4 was the more sensitive tool in judging the CTC
existence as well as the total number in patient blood. These
ﬁndings support the proposal of the potential role of CTC detec-
tion with adenovirus Ad5/35E1aPSESE4 as a molecular staging
tool of prostate cancer. Furthermore, our method for Ad5/
35E1aPSESE4 use detects only cells expressing PSA/PSMA proteins
and is able to count ﬂuorescent CTCs and to determine whether to
culture CTCs. At least 3 months after surgery, we detected CTCs in
29 of 85 localized prostate cancer patients who underwent radical
prostatectomy. Among 29 patients showing CTC in peripheral
blood, 27 patients still showed no biochemical evidence of tumor
recurrence, with an undetectable PSA level (PSA < 0.1 ng/mL). Fur-
thermore, 3 of 27 patients harbored cultivatable CTCs (Table 3).
Considering that the majority of CTCs originated from a primary
tumor are eliminated by a host defense mechanism, the detection
of CTCs that have not been eradicated in circulation is likely to
indicate tumor recurrence or residual tumors in the primary site
or a distant area. These discoveries demonstrate the potential role
of CTC detection by Ad5/35E1aPSESE4 for the prognostication of
prostate cancer after deﬁnite treatment including surgery. It would
be interesting to conduct a longer follow-up in order to conclude
whether clinically conﬁrmed tumor recurrence occurred in those
patients who presented with post-operative CTC detection. In
addition, we succeeded in in vitro CTC culturing and performing
Docetaxel-sensitivity tests (Fig. 5B), enabling our method to be
Table 3
PSA level in localized prostate cancer patients with CTC detection/cultivable cells.
Tumor stage CTC
detection
CTC culture
or not
Number of
patients
PSA <0.1 PSA ≥0.1
Localized
prostate
cancer
No No 28 27 1
Yes 3 0 3
Yes No 25 24 1
Yes 4 3 1
Fig. 5. Analysis of CTCs from patient blood marked by Ad5/35E1aPSESE4. A. PBMCs from ﬁve milliliters of blood in from localized prostate cancer patient were isolated as
described above and were infected with 0.01 MOI of Ad5/35E1aPSESE4. At 48 h post-infection, cells were observed under a ﬂuorescence microscope (left panel). Cultured
CTCs were conﬁrmed to be ﬂuorescent upon infection (right panel). B. Cultured CTCs of 3 × 103 were plated in a 96-well plate. Cell survival assays were performed to count
viable cells after exposure to docetaxel at different concentrations for 48 h. Cell viability was determined as a percentage of cells compared with the no-treatment control
(mean ± SEM; n = 3) in three independent experiments. The results were analyzed by two-tailed, paired t-tests. C. RNA-seq was performed as described in Materials and
Methods to characterize genes over-expressed in CTCs harvested from localized prostate cancer patients with PSA < 0.1 ng/mL.
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applied to patient-speciﬁc therapy through drug-sensitivity tests
or biologic phenotyping of cultured CTCs.
CTCs are present in the blood, and as a result, a so-called liquid
biopsy by a simple procedure has a strong advantage over regular
tissue biopsy, potentially providing a beneﬁt to patients [19]. There
are a number of clinical trials registered at www.clinicaltrials.gov
investigating CTCs as biomarkers. To date, much effort has been
exerted to develop a new detection method with better speciﬁcity
and sensitivity. The most well-established methods utilize epithe-
lial markers such as EpCAM [20] and CD45 [21]. These methods are
eﬃcient, but they have deﬁnite limitations in that large numbers
of CTCs lose their epithelial phenotypes in the blood. Alterna-
tively, CTCs of relatively large size are captured through small pores
that can separate them from small PBMCs. This method is also likely
to fail to capture cells as small as PBMCs, as some patients harbor
as few of the relatively small CTCs as one per 5 mL of blood. In par-
allel with the need for a better method is the introduction of
selectively labeling CTCs with a reporter gene delivered by RCA. De-
pending on the transcription regulator used to control RCA
replication, its sensitivity and speciﬁcity can be determined. The as-
sociation of cancer cells with the hTERT promoter was employed
to control the E1a gene of RCA, and hTERT-controlled RCA was
applied to CTCs originating from breast cancer [12]. Another RCA
for prostate CTC detection utilized a rat probasin promoter, and a
luciferase was secreted into culture media upon infection of pros-
tate cancer CTCs [13]. These two RCAs have distinct drawbacks in
that they are unable to mark suspended CTCs in blood from late-
stage prostate cancer patients. hTERT expression is not always high
in the late-stage tumor [22,23], and the probasin is dependent on
the androgen/androgen receptor. Probasin cannot be applied to CTCs
in patients undergoing hormone therapy and in the hormone-
deprivation stage. In our previous study, the PSES enhancer was
introduced to produce an RCA with prostate cell speciﬁcity. PSES
is a composite of two transcription regulatory elements control-
ling two common prostate speciﬁc proteins – PSA and PSMA [14]
– and mediates high transcription activity in PSA/PSMA-expressing
prostate cancer cells in the presence and absence of androgen. PSA
and PSMA genes are the two most well-known genes expressed by
the majority of androgen-dependent as well as androgen-
independent prostate cancers. Therefore, PSA and PSMA, with strong
androgen-independent promoter activity, make PSES superior to
probasin for the detection of CTCs from patients undergoing an-
drogen ablation therapy. Serum PSA has a limitation but is an
effective biomarker in correlation with disease status prior to pros-
tatectomy or hormone therapy.
The standard of care in ﬁrst-line metastatic castration-
resistant prostate cancer (mCRPC) is docetaxel-based chemotherapy.
Docetaxel with estramustine or prednisone can prolong survival
compared with mitoxantrone plus prednisone in mCRPC by a
median of approximately 18 months [24,25]. Recently, patient-
derived xenograft (PDX) has been employed to test the extent to
which a certain tumor is responsive prior to chemotherapy. However,
PDX is not well formed and does not reﬂect tumor heterogeneity.
In this study, CTCs from many CRPC patients were cultured to
enable further drug sensitivity tests, suggesting that some of the
mCRPC patients could have beneﬁted from CTC evaluation in
determining the most effective chemotherapy regime. Further-
more, in cases of chemotherapy resistance, genome analysis of
CTC culture would be useful to understand resistance mecha-
nisms, as resistance depends on the genetic mutations of prostate
tumors. Our data highlight a novel strategy to detect CTCs by a
PSES-controlled adenovirus, which effectively marks prostate cancer
cells in patient blood. Because CTCs reﬂect the patient status for
potential recurrence and disease progression, Ad5/35E1aPSESE4-
mediated CTC detection accompanied by the identiﬁcation of
CTCs is worthy of further investigation.
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